154 related articles for article (PubMed ID: 32048382)
1. Number of mesothelial cells as a measure of adequacy criteria for pleural effusions: A multi-institutional study.
Rodriguez EF; Morris PC; Calsavara V; Pastorello RG; Saieg M
Cytopathology; 2020 May; 31(3):223-227. PubMed ID: 32048382
[TBL] [Abstract][Full Text] [Related]
2. Small orangiophilic squamous-like cells: an underrecognized and useful morphological feature for the diagnosis of malignant mesothelioma in pleural effusion cytology.
Chen L; Caldero SG; Gmitro S; Smith ML; De Petris G; Zarka MA
Cancer Cytopathol; 2014 Jan; 122(1):70-5. PubMed ID: 23983174
[TBL] [Abstract][Full Text] [Related]
3. Cytohistological correlation in serous effusions using the newly proposed International System for Reporting Serous Fluid Cytopathology: Experience of an oncological center.
Lobo C; Costa J; Petronilho S; Monteiro P; Leça L; Schmitt F
Diagn Cytopathol; 2021 May; 49(5):596-605. PubMed ID: 32339444
[TBL] [Abstract][Full Text] [Related]
4. Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry.
Su XY; Li GD; Liu WP; Xie B; Jiang YH
Diagn Cytopathol; 2011 Dec; 39(12):900-8. PubMed ID: 20836004
[TBL] [Abstract][Full Text] [Related]
5. Pleural fluid cell-free DNA integrity index to identify cytologically negative malignant pleural effusions including mesotheliomas.
Sriram KB; Relan V; Clarke BE; Duhig EE; Windsor MN; Matar KS; Naidoo R; Passmore L; McCaul E; Courtney D; Yang IA; Bowman RV; Fong KM
BMC Cancer; 2012 Sep; 12():428. PubMed ID: 23009708
[TBL] [Abstract][Full Text] [Related]
6. Adequacy in pleural effusion: What is the minimum volume required for detection of malignant cells?
Jha S; Sethy M; Sharma G; Adhya AK
Diagn Cytopathol; 2022 Jun; 50(6):284-288. PubMed ID: 35362266
[TBL] [Abstract][Full Text] [Related]
7. Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions.
Hanley KZ; Facik MS; Bourne PA; Yang Q; Spaulding BO; Bonfiglio TA; Xu H
Cancer; 2008 Feb; 114(1):49-56. PubMed ID: 18098206
[TBL] [Abstract][Full Text] [Related]
8. Calretinin. A selective marker of normal and neoplastic mesothelial cells in serous effusions.
Barberis MC; Faleri M; Veronese S; Casadio C; Viale G
Acta Cytol; 1997; 41(6):1757-61. PubMed ID: 9390137
[TBL] [Abstract][Full Text] [Related]
9. Loss of BRCA1-associated protein 1 (BAP1) expression is useful in diagnostic cytopathology of malignant mesothelioma in effusions.
Cozzi I; Oprescu FA; Rullo E; Ascoli V
Diagn Cytopathol; 2018 Jan; 46(1):9-14. PubMed ID: 28994508
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic yield of pleural fluid cytology in malignant effusions: an Australian tertiary centre experience.
Loveland P; Christie M; Hammerschlag G; Irving L; Steinfort D
Intern Med J; 2018 Nov; 48(11):1318-1324. PubMed ID: 29869427
[TBL] [Abstract][Full Text] [Related]
11. BAP1 Immunostain and CDKN2A (p16) FISH Analysis: Clinical Applicability for the Diagnosis of Malignant Mesothelioma in Effusions.
Walts AE; Hiroshima K; McGregor SM; Wu D; Husain AN; Marchevsky AM
Diagn Cytopathol; 2016 Jul; 44(7):599-606. PubMed ID: 27121152
[TBL] [Abstract][Full Text] [Related]
12. The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions.
Illei PB; Ladanyi M; Rusch VW; Zakowski MF
Cancer; 2003 Feb; 99(1):51-6. PubMed ID: 12589646
[TBL] [Abstract][Full Text] [Related]
13. IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: the expression profiles of IMP3/L523S in effusion cytology.
Ikeda K; Tate G; Suzuki T; Kitamura T; Mitsuya T
Hum Pathol; 2010 May; 41(5):745-50. PubMed ID: 20060157
[TBL] [Abstract][Full Text] [Related]
14. Idiopathic Pleural Effusions: Characteristics and Discrimination From Cytology-Negative Malignant Pleural Effusions.
Park JE; Do YW; Lee DH; Lee SY; Lim JK; Choi SH; Seo HW; Yoo SS; Lee SY; Cha SI; Park JY; Lee J; Kim CH
Am J Med Sci; 2020 Sep; 360(3):236-242. PubMed ID: 32423747
[TBL] [Abstract][Full Text] [Related]
15. The cytological features of effusions with mesothelioma in situ: A report of 9 cases.
Michael CW; Bedrossian CCWM; Sadri N; Klebe S
Diagn Cytopathol; 2023 Jun; 51(6):374-388. PubMed ID: 36942732
[TBL] [Abstract][Full Text] [Related]
16. Cytologic re-evaluation of negative effusions from patients with malignant mesothelioma.
Ascoli V; Bosco D; Carnovale Scalzo C
Pathologica; 2011 Dec; 103(6):318-24. PubMed ID: 22558888
[TBL] [Abstract][Full Text] [Related]
17. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids.
Politi E; Kandaraki C; Apostolopoulou C; Kyritsi T; Koutselini H
Diagn Cytopathol; 2005 Mar; 32(3):151-5. PubMed ID: 15690338
[TBL] [Abstract][Full Text] [Related]
18. Morphological markers of chromosomal instability as predictors of malignancy in pleural effusion.
Aggarwal P; Handa U; Bhagat R; Aggarwal D
Diagn Cytopathol; 2024 Feb; 52(2):76-81. PubMed ID: 37946685
[TBL] [Abstract][Full Text] [Related]
19. CEA, AFP, CA125, CA153 and CA199 in malignant pleural effusions predict the cause.
Wang XF; Wu YH; Wang MS; Wang YS
Asian Pac J Cancer Prev; 2014; 15(1):363-8. PubMed ID: 24528057
[TBL] [Abstract][Full Text] [Related]
20. The diagnosis of malignant mesothelioma in effusion cytology: a reappraisal and results of a multi-institution survey.
Paintal A; Raparia K; Zakowski MF; Nayar R
Cancer Cytopathol; 2013 Dec; 121(12):703-7. PubMed ID: 24039177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
